Raveron versus placebo in the conservative treatment of benign prostatic hyperplasia (BPH).
Thirty patients with BPH were randomized into two groups to receive Raveron and placebo for 6 weeks. The subjective and objective signs associated with BPH were evaluated before and after treatment. There was no significant difference between the effects of Raveron and placebo.
Department of Urology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
K
K
Bircan
H A
HA
Ozen
A
A
Ergen
I
I
Başar
S
S
Ozgür
Y
Y
Ilker
E
E
Karaağaoğlu
D
D
Remzi
D004311:Double-Blind Method; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D014020:Tissue Extracts / Q000627:therapeutic use*; D014563:Urodynamics / Q000187:drug effects
D010919:Placebos; C012025:Robaveron; D014020:Tissue Extracts